Understand European GMPs and the Role of the QP

7 - 8 June 2011, Washington D.C. Metro Area, USA.
With optional Post-Conference Sessions on June 9, 2011.
Over the past few years the role and duties of the Qualified Person keep increasing in significance and scope. Being the key person in the quality function of a pharmaceutical company, the QP has to consider many issues to fulfil the responsibilities and to comply with the European legislation.

This Conference is designed by QPs and international Experts as a forum with focus on sharing information and experience and on discussing the critical areas of European GMPs and the QP's daily work.

The Conference has been designed for non-European QA and QCU personnel, upper management functions and authority representatives who want to be informed about the latest development regarding European GMPs and the duties and responsibilities of Qualified Persons.

Speakers:

  • Richard M. Bonner, Qualified Person, Formerly with Eli Lilly and Company Ltd., UK
  • Dr Christopher Burgess, Qualified Person, Burgess Analytical Consultancy, UK
  • Dr Dimitrios Catsoulacos, European Medicines Agency, EMA
  • Dr Bernd Renger, Qualified Person, Chairman, European QP Association
  • Dr Janice Soreth, FDA, Office of International Programs at EMA
  • Martine Tratsaert, Qualified Person, Johnson & Johnson, Belgium
  • Mark Tucker, Ph.D., Genentech Inc./Roche Group, USA

Highlights
Understand European GMPs

  • ƒ The European Pharmaceutical Legislation
  • ƒƒ Import/ Export, CEPs and GMP Certificates
  • ƒƒ EU Product Quality Review Requirements versus US Annual Report Requirements

Understand the Role of the QP

    ƒƒ
  • The Legal and Professional Duties of the Qualified Person
  • ƒ EU Inspections in the U.S. and the Involvement of the QP
  • ƒƒ The EU Discretion Paper and the Release of Batches by the QP
  • ƒƒ The Role of the QP in Contract Manufacturing
  • ƒƒ The role of the QP in the Supply Chain and Supplier Qualification
  • ƒƒ The US Quality Unit versus the EU QP

The view of FDA and EMA
With optional Post-Conference Sessions on June 9, 2011

  • ƒƒ Session 1: Case studies: Certification by a QP and Batch Release
  • ƒƒ Session 2: Clinical Trial Supplies: IMP Handling in Europe and the Role of the QP

For further information and registration, please visit:
http://www.gmp-compliance.org/qpag_forum_5.html

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...